Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study

Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study

This Italian observational real-world study aims to assess in chronic hepatitis C virus (HCV) patients treated with pangenotypic direct acting agents (pDAAs) glecaprevir/pibrentasvir (GLE/PIB) or sofosbuvir/velpatasvir (SOF/VEL) the potential drug–drug interactions (DDIs) with concomitant medication...

Full description

Bibliographic Details
Main Authors: Alessandra Mangia, Francesco Scaglione, Pierluigi Toniutto, Mario Pirisi, Nicola Coppola, Giovanni Di Perri, Gema Alvarez Nieto, Stefano Calabrese, Candido Hernandez, Valentina Perrone, Luca Degli Esposti, Stefano Fagiuoli
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:International Journal of Environmental Research and Public Health
Subjects:
drug–drug interactions
glecaprevir/pibrentasvir
HCV
sofosbuvir/velpatasvir
Online Access:https://www.mdpi.com/1660-4601/18/13/7144

Internet

https://www.mdpi.com/1660-4601/18/13/7144

Similar Items